Imaging plays a major and growing role in noninvasively assessing cancer biology, preclinically and in clinical translational studies. Imaging is now being used to personalize therapies in clinical practice. In early and advanced clinical trials of cancer therapeutics, imaging can provide key information on the mechanisms of action of the treatment, including whether target lesions are present, whether the target lesion is ?hit? by the therapy, whether the cancer is responding and if tumor progression has occurred. Elements of such measurements are an important part of many studies involving cancer therapy conducted at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Qualitative imaging is now being complemented by sophisticated quantitative approaches. To assure access to advanced imaging technologies, including quantitative PET, MRI and CT, the Imaging Response Assessment (IRAT) Core was established within the SKCCC. Services of the IRAT available to SKCCC investigators include: a) consultation and guidance on the proper choice, design and use of imaging studies in clinical trials; b) expert reviews of clinical protocols to assure that the imaging protocol and analysis plans are appropriate for the chosen task; c) state-of-the-art prompt and accurate assessment of tumor response using standardized anatomic and metabolic response criteria, including Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and PET Response Criteria in Solid Tumors (PERCIST) 1.0; d) image archival, anonymization and data import/export; e) developing documents, protocols and forms to assist in studies performed at one or multiple sites; f) regulatory guidance on radiation exposure and molecular imaging agents; g) assisting in development of nontraditional imaging metrics for response assessment, including participation in ACRIN and ECOG trials; and h) improving collaborations among SKCCC investigators and imaging specialists in quantitative imaging. Future plans include new and advanced computing and software platforms to continue to provide robust quantitative analyses of single and multimodality imaging studies of cancer treatment response with current and emerging imaging tools. IRAT input into study design and analysis is expected to lead to more appropriate, accurate and reproducible imaging in cancer therapy studies performed at The Johns Hopkins University (JHU) and in collaboration with other institutions. Appropriate quantitative imaging will benefit clinical cancer therapy trials of all phases and should accelerate translational cancer research. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-55
Application #
9519880
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151

Showing the most recent 10 out of 2393 publications